NYSE American - Delayed Quote
USD
Oragenics, Inc. (OGEN)
0.3492
+0.0001
(+0.04%)
At close: November 6 at 3:58:41 PM EST
Key Executives
Amounts are as of December 31, 2025 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Ms. Janet Huffman
|
CEO, President, Secretary & Treasurer | 407.46k | -- | 1972 |
|
Mr. John Spencer
|
Chief Financial Officer | -- | -- | 1994 |
|
Dr. James P. Kelly M.A., M.D.
|
Chief Medical Officer | -- | -- | -- |
|
Dr. William Franklin Peacock IV, F.A.C.E.P., FACC, M.D.
|
Chief Clinical Officer | -- | -- | -- |
Oragenics, Inc.
9015 Town Center Parkway
Suite 143
Lakewood Ranch, FL 34202
United States
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 3
Description
Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification for the treatment of mild traumatic brain injury. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Lakewood Ranch, Florida.
Corporate Governance
Oragenics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of
Institutional Shareholder Services (ISS)
Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
Upcoming Events Information Not Available
